---
title: "Arcturus Therapeutics partners with Thermo Fisher to support Phase 3 development of cystic fibrosis therapy ARCT-032"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291536254.md"
description: "Arcturus Therapeutics has entered a strategic collaboration with Thermo Fisher to support the Phase 3 development of ARCT-032, an investigational mRNA therapy for cystic fibrosis. Under the agreement, Thermo Fisher will provide integrated manufacturing and clinical research services via its Accelerator Drug Development platform. If Phase 2 results are positive, Arcturus plans to conduct Phase 3 trials through Thermo Fisher’s PPD unit. Additionally, subject to regulatory approval, Thermo Fisher will secure exclusive commercial manufacturing rights under a separate agreement."
datetime: "2026-07-02T11:00:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291536254.md)
  - [en](https://longbridge.com/en/news/291536254.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291536254.md)
generator: "portal-rs"
---

# Arcturus Therapeutics partners with Thermo Fisher to support Phase 3 development of cystic fibrosis therapy ARCT-032

-   Arcturus entered a strategic collaboration with Thermo Fisher to support Phase 3 development of ARCT-032, its investigational mRNA therapy for cystic fibrosis. \* Thermo Fisher will provide integrated manufacturing, clinical research, commercial readiness services via its Accelerator Drug Development platform. \* Thermo Fisher will supply Phase 3 manufacturing services; Arcturus expects to run Phase 3 through Thermo Fisher’s PPD clinical research unit if Phase 2 is positive. \* Subject to regulatory approval, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate commercial agreement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607020700BIZWIRE\_USPR\_\_\_\_\_20260702\_BW861323) on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [TMO.US](https://longbridge.com/en/quote/TMO.US.md)

## Related News & Research

- [Farther Finance Advisors LLC Has $6.57 Million Holdings in Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/296071305.md)
- [Cannon Advisors Inc. Acquires New Shares in Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/295995394.md)
- [Simplify Asset Management Inc. Buys 5,670 Shares of Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/296019005.md)
- [Avalon Trust Co Buys Shares of 35,466 Thermo Fisher Scientific Inc. $TMO](https://longbridge.com/en/news/296188981.md)
- [Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline](https://longbridge.com/en/news/295596260.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**